Next Article in Journal
Mammalian DNA Polymerase Kappa Activity and Specificity
Next Article in Special Issue
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model
Previous Article in Journal
Galactosaminoglycans: Medical Applications and Drawbacks
Previous Article in Special Issue
Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa
Article

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?

1
Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland
2
Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, 30-663 Krakow, Poland
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(15), 2804; https://doi.org/10.3390/molecules24152804
Received: 1 July 2019 / Revised: 29 July 2019 / Accepted: 30 July 2019 / Published: 1 August 2019
(This article belongs to the Special Issue Recent Advances in Anticancer Drugs)
CA-170 is currently the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins – important negative checkpoint regulators of immune activation. The reported therapeutic results to some extent mimic those of FDA-approved monoclonal antibodies overcoming the limitations of the high production costs and adverse effects of the latter. However, no conclusive biophysical evidence proving the binding to hPD-L1 has ever been presented. Using well-known in vitro methods: NMR binding assay, HTRF and cell-based activation assays, we clearly show that there is no direct binding between CA-170 and PD-L1. To strengthen our reasoning, we performed control experiments on AUNP-12 – a 29-mer peptide, which is a precursor of CA-170. Positive controls consisted of the well-documented small-molecule PD-L1 inhibitors: BMS-1166 and peptide-57. View Full-Text
Keywords: CA-170; PD-1/PD-L1; NMR; HTRF; immune checkpoint CA-170; PD-1/PD-L1; NMR; HTRF; immune checkpoint
Show Figures

Figure 1

MDPI and ACS Style

Musielak, B.; Kocik, J.; Skalniak, L.; Magiera-Mularz, K.; Sala, D.; Czub, M.; Stec, M.; Siedlar, M.; Holak, T.A.; Plewka, J. CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? Molecules 2019, 24, 2804. https://doi.org/10.3390/molecules24152804

AMA Style

Musielak B, Kocik J, Skalniak L, Magiera-Mularz K, Sala D, Czub M, Stec M, Siedlar M, Holak TA, Plewka J. CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? Molecules. 2019; 24(15):2804. https://doi.org/10.3390/molecules24152804

Chicago/Turabian Style

Musielak, Bogdan, Justyna Kocik, Lukasz Skalniak, Katarzyna Magiera-Mularz, Dominik Sala, Miroslawa Czub, Malgorzata Stec, Maciej Siedlar, Tad A. Holak, and Jacek Plewka. 2019. "CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?" Molecules 24, no. 15: 2804. https://doi.org/10.3390/molecules24152804

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop